Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04149535 · ClinicalTrials.gov registry record · NA
PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 3,000
- Enrollment target
NCT04149535 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 3,000 participants.
The verdict
NCT04149535, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,000 participants
- Enrollment target
Study Summary
To demonstrate that use of the Sentinel® Cerebral Protection System significantly reduces the risk of peri-procedural stroke (≤72 hours) after transcatheter aortic valve replacement (TAVR).
Interventions
- DEVICE Sentinel® Cerebral Protection System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2020-02-07 |
| Est. Completion | 2022-02-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04149535
The ClinicalTrials.gov registry entry for NCT04149535 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sentinel® Cerebral Protection System is the first listed.
NCT04149535 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04149535 about?
NCT04149535 is a clinical study titled "PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement". To demonstrate that use of the Sentinel® Cerebral Protection System significantly reduces the risk of peri-procedural stroke (≤72 hours) after transcatheter aortic valve replacement (TAVR).
What is the current status of trial NCT04149535?
This trial is currently completed. It is a NA study. The enrollment target is 3,000 participants. The study started on 2020-02-07. Estimated completion is 2022-02-01.
What interventions are being tested in trial NCT04149535?
The interventions under investigation include: Sentinel® Cerebral Protection System (DEVICE).
Who is sponsoring clinical trial NCT04149535?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.